Top

High Blood Pressure & Cardiovascular Prevention

Published in:

01-11-2022 | Cough | Review article

Evaluation of the Safety and Efficacy of Dual Therapy Perindopril/Amlodipine in the Management of Hypertension. A Systematic Review and Meta-Analysis

Authors: Sadek Mostafa, Hosam Shabana, Farag Khalil, Ismail Mohamed El Mancy, Hendawy Abdel-Moety Zedan, Ahmed Elmoursi, Ibrahim Ghounim Ramadan, Saad El Deen Mohamed, Arafat Kassem, Islam Shawky Kamel

Published in: High Blood Pressure & Cardiovascular Prevention | Issue 6/2022

Abstract

Introduction

Hypertension represent the commonest cause of death in 2017. Hypertension is classified into two types which are primary or essential hypertension and secondary hypertension. The perindopril–amlodipine combination showed a significant effect in reduction of the elevated BP and the cardiovascular complications.

Aim

To evaluate the efficacy and safety of a fixed-dose single-pill combination of perindopril–amlodipine in hypertensive patients.

Methods

We searched PubMed, Medline, SCOPUS, and Web of Science for relevant clinical trials. Quality appraisal was evaluated according to GRADE and we assessed the risk of bias using Cochrane’s risk of bias tool. We included the following outcomes: systolic blood pressure, diastolic blood pressure, pulse pressure, mean blood pressure, heart rate, cough, dizziness, headache, and peripheral edema. We performed the analysis of homogeneous data under the fixed-effects model, while analysis of heterogeneous data was analyzed under the random-effects model. We conducted a meta-regression according to the dose.

Results

We included ten clinical trials. The pooled analysis showed that there was a significant reduction of the systolic blood pressure, diastolic blood pressure, pulse plessure, mean blood pressure, and heart rate after the the perindopril–amlodipine combination (MD = 18.96 [14.32, 23.60], P < 0.0001), (MD = 11.90 [8.45, 15.35], P < 0.0001), (MD = 8.44 [6.91, 9.97], P = 0.0001), (MD = 13.07 [5.86, 20.29], P = 0.0004), and (MD = 2.93 [0.89, 4.96], P = 0.005), respectively. The results of the meta-regression revealed that the efficacy is increased by increasing the dose (P < 0.001)

Conclusion

The use of the perindopril–amlodipine combination had a significant effect on the reduction of SBP, DBP, mean blood pressure, pulse pressure, and HR.

Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical Pr. J Am Coll Cardiol. 2018;71:e127–248.CrossRefPubMed

Erratum: Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of Di. Lancet. 2019.

Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Kardiol Pol. 2019;77:71–159.CrossRefPubMed

Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, Cífková R, Dominiczak AF et al. Hypertension. Nat Rev Dis Prim. 2018;18014. Available from: http://www.nature.com/articles/nrdp201814

Fagard R, Brguljan J, Staessen J, Thijs L, Derom C, Thomis M, et al. Heritability of conventional an ambulatory blood pressures: a study in twins. Hypertension. 1995;26:919–24.CrossRefPubMed

Streeten DHP, Anderson GH. Secondary hypertension. Drugs. 1992;43:805–19.CrossRefPubMed

Hosseinnezhad A, Black RM, Aeddula NR, Adhikari D, Trivedi N. Glucagon-induced pheochromocytoma crisis. Endocr Pract. 2011;17:e51–4.CrossRefPubMed

Biswas S, Dastidar DG, Roy KS, Pal SK, Biswas TK, Ganguly SB. Complications of hypertension as encountered by primary care physician. J Indian Med Assoc. 2003;101:257–9.PubMed

James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults. JAMA. 2014;311:507.CrossRefPubMed

10.

Leape L, Berwick D, Clancy C, Conway J, Gluck P, Guest J, et al. Transforming healthcare: a safety imperative. Qual Saf Heal Care. 2009;18:424–8.CrossRef

11.

Turnbull F. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Arch Intern Med. 2005;165:1410.CrossRefPubMed

12.

Turnbull F, Neal B, Algert C, Chalmers J, Woodward M, MacMahon S, et al. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527–35.CrossRefPubMed

13.

Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122:290–300.CrossRefPubMed

14.

Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials. Br Med J. 2003;326:1427.CrossRef

15.

Dimmitt SB, Stampfer HG. Low drug doses may improve outcomes in chronic disease. Med J Aust. 2009;191:511–3.CrossRefPubMed

16.

Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-B). Lancet. 2005;366:895–906.CrossRefPubMed

17.

Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120:713–9.CrossRefPubMed

18.

Hamrahian SM. Medication non-adherence: a major cause of resistant hypertension. Curr Cardiol Rep. 2020;22:133. https://doi.org/10.1007/s11886-020-01400-3.CrossRefPubMed

19.

Hurst M, Jarvis B. Perindopril: an updated review of its use in hypertension. Drugs. 2001;61:867–96. https://doi.org/10.2165/00003495-200161060-00020.CrossRefPubMed

20.

Fares H, DiNicolantonio JJ, O’Keefe JH, Lavie CJ. Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes. Open Heart. 2016;3: e000473. https://doi.org/10.1136/openhrt-2016-000473.CrossRefPubMedPubMedCentral

21.

Taylor SH. Usefulness of amlodipine for angina pectoris. Am J Cardiol. 1994;73:A28–33.CrossRef

22.

Gradman AH, Cutler NR, Davis PJ, Robbins JA, Weiss RJ, Wood BC. Combined enalapril and felodipine extended release (ER) for systemic hypertension. Am J Cardiol. 1997;79:431–5.CrossRefPubMed

23.

Moher D, Liberati A, Tetzlaff J, Altman DG, Antes G, Atkins D, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Rev Esp Nutr Humana Diet. 2014. https://doi.org/10.1186/2046-4053-4-1.CrossRef

24.

Katz A. Microsoft Excel 2010. Style (DeKalb, IL). 2010.

25.

Clarivate EndNote | Available from: https://endnote.com/.

26.

Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ et al. Cochrane handbook for systematic reviews of interventions. 2019.

27.

Ojji DB, Mayosi B, Francis V, Badri M, Cornelius V, Smythe W, et al. Comparison of dual therapies for lowering blood pressure in black Africans. N Engl J Med. 2019;380:2429–39. https://doi.org/10.1056/NEJMoa1901113.CrossRefPubMed

28.

Mancia G, Asmar R, Amodeo C, Mourad J-J, Taddei S, Gamba MAA, et al. Comparison of single-pill strategies first line in hypertension. J Hypertens. 2015;33:401–11.CrossRefPubMed

29.

Laurent S, Parati G, Chazova I, Sirenko Y, Erglis A, Laucevicius A, et al. Randomized evaluation of a novel, fixed-dose combination of perindopril 3.5 mg/amlodipine 2.5 mg as a first-step treatment in hypertension. J Hypertens. 2015;33:653–62.CrossRefPubMed

30.

Hu D, Sun Y, Liao Y, Huang J, Zhao R, Yang K. Efficacy and safety of fixed-dose perindopril arginine/amlodipine in hypertensive patients not adequately controlled with amlodipine 5 mg or perindopril tert-butylamine 4 mg monotherapy. Cardiology. 2016;134:1–10.CrossRefPubMed

31.

Elliott WJ, Whitmore J, Feldstein JD, Bakris GL. Efficacy and safety of perindopril arginine + amlodipine in hypertension. J Am Soc Hypertens. 2015. https://doi.org/10.1016/j.jash.2015.01.012.CrossRefPubMed

32.

Visco V, Finelli R, Pascale AV, Giannotti R, Fabbricatore D, Ragosa N, et al. Larger blood pressure reduction by fixed-dose compared to free dose combination therapy of ACE inhibitor and calcium antagonist in hypertensive patients. Transl Med. 2017;16:17–23.

33.

Sobngwi E, Mfeukeu-Kuate L, Kouam M, Tankeu AT, Nganou-Gnindjio CN, Hamadou B, et al. Short-term effects of perindopril-amlodipine vs perindopril-indapamide on blood pressure control in sub-Saharan type 2 diabetic individuals newly diagnosed for hypertension: a double-blinded randomized controlled trial. J Clin Hypertens. 2019;21:1002–8. https://doi.org/10.1111/jch.13557.CrossRef

34.

Redon J, Pichler G. Comparative study of the efficacy of olmesartan/amlodipine vs. perindopril/amlodipine in peripheral blood pressure after missed dose in type 2 diabetes. J Hypertens. 2016;34:359–67.CrossRefPubMed

35.

Ramirez AJ, Sanchez MJ, Sanchez RA. Diabetic patients with essential hypertension treated with amlodipine. J Hypertens. 2019;37:636–42.CrossRefPubMed

36.

Poulter NR, Dolan E, Gupta AK, O’Brien E, Whitehouse A, Sever PS. Efficacy and safety of incremental dosing of a new single-pill formulation of perindopril and amlodipine in the management of hypertension. Am J Cardiovasc Drugs. 2019;19:313–23. https://doi.org/10.1007/s40256-018-00314-4.CrossRefPubMed

37.

Jamerson KA, Nwose O, Jean-Louis L, Schofield L, Purkayastha D, Baron M. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am J Hypertens. 2004;17:495–501.CrossRefPubMed

38.

Philipp T, Glazer RD, Wernsing M, Yen J. Initial combination therapy with amlodipine/valsartan compared with monotherapy in the treatment of hypertension. J Am Soc Hypertens. 2011;5:417–24.CrossRefPubMed

39.

Chrysant SG, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther. 2008;30:587–604.CrossRefPubMed

40.

Littlejohn TW, Majul CR, Olvera R, Seeber M, Kobe M, Guthrie R, et al. Results of treatment with telmisartan-amlodipine in hypertensive patients. J Clin Hypertens. 2009;11:207–13.CrossRef

41.

Brown MJ, McInnes GT, Papst CC, Zhang J, MacDonald TM. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet. 2011;377:312–20.CrossRefPubMed

42.

Packard KA, Wurdeman RL, Arouni AJ. ACE inhibitor-induced bronchial reactivity in patients with respiratory dysfunction. Ann Pharmacother. 2002;36:1058–67.CrossRefPubMed

43.

Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159–219.CrossRefPubMed

44.

Hackam DG, Khan NA, Hemmelgarn BR, Rabkin SW, Touyz RM, Campbell NRC, et al. The 2010 Canadian hypertension education program recommendations for the management of hypertension: part 2—therapy. Can J Cardiol. 2010;26:249–58.CrossRefPubMedPubMedCentral

45.

Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206–52. https://doi.org/10.1161/01.HYP.0000107251.49515.c2.CrossRefPubMed

46.

Sofy AA, Abdelsattar AT, Mohammed OM, Shareef MA, Alamodi AA, Nso N, et al. Amlodipine compared with benidipine in the management of hypertension: a systematic review and meta-analysis. High Blood Press Cardiovasc Prev. 2020;27:527–37. https://doi.org/10.1007/s40292-020-00412-y.CrossRefPubMed

47.

Habboush S, Sofy AA, Masoud AT, Cherfaoui O, Farhat AM, Abdelsattar AT, et al. Efficacy of single-pill, triple antihypertensive therapy in patients with uncontrolled hypertension: a systematic review and meta-analysis. High Blood Press Cardiovasc Prev. 2022;29:245–52. https://doi.org/10.1007/s40292-022-00511-y.CrossRefPubMed

48.

Mourad J-J, Waeber B, Zannad F, Laville M, Duru G, Andrjak M. Comparison of different therapeutic strategies in hypertension. J Hypertens. 2004;22:2379–86.CrossRefPubMed

49.

Correction. J Am Coll Cardiol. 2011;57:2125. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0735109711013246

50.

van Vark LC, Bertrand M, Akkerhuis KM, Brugts JJ, Fox K, Mourad J-J, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158 998 patients. Eur Heart J. 2012;33:2088–97. https://doi.org/10.1093/eurheartj/ehs075.CrossRefPubMedPubMedCentral

51.

Schünemann HJ, Higgins JPT, Vist GE, Glasziou P, Akl EA, Skoetz N, et al. Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JPT, et al., editors. Cochrane Handb. Syst. Rev. Interv. Boca Raton: Wiley; 2019. p. 375–402.CrossRef

Title: Evaluation of the Safety and Efficacy of Dual Therapy Perindopril/Amlodipine in the Management of Hypertension. A Systematic Review and Meta-Analysis
Authors: Sadek Mostafa
Hosam Shabana
Farag Khalil
Ismail Mohamed El Mancy
Hendawy Abdel-Moety Zedan
Ahmed Elmoursi
Ibrahim Ghounim Ramadan
Saad El Deen Mohamed
Arafat Kassem
Islam Shawky Kamel
Publication date: 01-11-2022
Publisher: Springer International Publishing
Keywords: Cough
Perindopril
Cough
Amlodipine
Cough
Hypertension
Hypertension
Published in: High Blood Pressure & Cardiovascular Prevention / Issue 6/2022
Print ISSN: 1120-9879
Electronic ISSN: 1179-1985
DOI: https://doi.org/10.1007/s40292-022-00544-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Evaluation of the Safety and Efficacy of Dual Therapy Perindopril/Amlodipine in the Management of Hypertension. A Systematic Review and Meta-Analysis

Abstract

Introduction

Aim

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Aim

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2022

Evaluating Adherence to Concomitant Diabetes, Hypertension, and Hyperlipidemia Treatments and Cardiovascular Outcomes Among Elderly Patients Using Marginal Structural Modeling

HOMA-IR as a predictor of Health Outcomes in Patients with Metabolic Risk Factors: A Systematic Review and Meta-analysis

Subclinical HMOD in Hypertension: Left Ventricular Diastolic Dysfunction

Subclinical HMOD in Hypertension: Brain Imaging and Cognitive Function

Relationship Between Calcium Channel Blockers Therapy and Cognitive Function Improvement in Cognitive Decline Patients with Cerebrovascular Disease

The Association Between Dietary Inflammatory Index (DII) and Risk of Hypertension: A Case–Control Study